Testosterone had no effect on the risk of arrhythmia, coronary heart disease, heart failure and myocardial infarction. Short-term treatment of hypogonadism with drugs male sex hormone safe for the cardiovascular system.
Scientists have found no evidence that testosterone increases short- and medium-term cardiovascular risks in men with hypogonadism. The results of the study were presented by researchers at the University of Aberdeen in the journal The Lancet Healthy Longevity.
|An extensive analysis of data from testosterone trials examined the subtypes of cardiovascular events observed during treatment, as well as the effect of drug use. The review and meta-analysis of randomized controlled trials included men aged 18 years or older with a testosterone concentration of 12 nmol/L (350 ng/dL) or less and who had been treated with the drug for three months. Risk of bias was assessed using the Cochrane Risk of Bias tool.
Fewer deaths occurred with testosterone treatment (6 of 1621, or 0.4%) than with placebo (12 of 1537, or 0.8%), with no significant differences between groups. Cardiovascular risk was similar.
Cardiovascular complications included arrhythmia, coronary heart disease, heart failure, and myocardial infarction. Patients’ general age, baseline testosterone levels, smoking status, or diabetes status were not associated with cardiovascular risk.